The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Glycosaminoglycan-lipoprotein interaction
Abstract
Glycosaminoglycans (GAGs) bound to various proteoglycans (PGs) present in the cardiovascular system have been proposed to perform a wide range of functions. These include conferring viscoelastic properties; interacting with and modulating growth factors and enzymes; and as receptors and co-receptors in lipoprotein metabolism. Binding of apoB-100 lipoproteins, particularly low density lipoproteins (LDL), to GAGs of extracellular matrix PGs in arteries has been proposed to be an initiating event in development of atherosclerosis. This study was initiated with the aim of getting an overview of the binding patterns of different lipoprotein subclasses with individual GAG categories. We thus evaluated the interaction of lipoproteins with GAGs commonly found in the cardiovascular system using a gel mobility-shift assay developed for this purpose. The same procedure was used to measure lipoproteins binding to metabolically [(35)S]-labeled whole PGs prepared from three cell types, arterial smooth muscle cells, THP-1 macrophages and from HepG2 cells. The effect of GAG composition on PGs on lipoprotein binding was evaluated by enzymatic degradation of the carbohydrate chains. Heparan sulfate was found to bind beta very low density lipoproteins (beta-VLDL) and a chylomicron remnant model (beta-VLDL+apoE), but not LDL. Dermatan sulfate was found to bind LDL, but not beta-VLDL or the chylomicron remnant model. Chondroitin sulfate and heparin were found to bind all lipoproteins tested (LDL, beta-VLDL and beta-VLDL+apoE) although with different affinities. We can conclude that each lipoprotein subclass tested binds a specific assortment of the GAGs tested. The observations made contribute to the understanding of new and complex mechanisms by which carbohydrate and lipid metabolism may be linked.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Although the variations in the distribution of acidic groups in different types of GAG (31) are likely to influence the interaction with apoE (32, 33)”
From Role of the N- and C-Terminal Domains in Binding of Apolipoprotein E Isoforms to Heparan Sulfate and Dermatan Sulfate: A Surface Plasmon Resonance Study (2008) · cites this paper as [32]
Citations
Cites
Negative regulation of transforming growth factor-β by the proteoglycan decorin
Yamaguchi, Y., Mann, D. M., & Ruoslahti, E. (1990) · Nature · doi:10.1038/346281a0 · Cited by 1,516
Glycosaminoglycans: molecular properties, protein interactions, and role in physiological processes
Jackson, R. L., Busch, S. J., & Cardin, A. D. (1991) · Physiological Reviews · doi:10.1152/physrev.1991.71.2.481 · Cited by 1,104
Mahley, R. W., & Ji, Z.-S. (1999) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)33334-4 · Cited by 693
Synthesis and sorting of proteoglycans
Prydz, K., & Dalen, K. T. (2000) · Journal of Cell Science · doi:10.1242/jcs.113.2.193 · Cited by 481
The Interaction between Human Plasma Lipoproteins and Connective Tissue Glycosaminoglycans
Iverius, P. (1972) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)45469-0 · Cited by 462
Hep G2 cells as a resource for metabolic studies: lipoprotein, cholesterol, and bile acids
Javitt, N. B. (1990) · The FASEB Journal · doi:10.1096/fasebj.4.2.2153592 · Cited by 357
The Relationship Between Plasma and Tissue Lipids in Human Atherosclerosis
Smith, E. B. (1974) · Advances in lipid research · doi:10.1016/b978-0-12-024912-1.50008-9 · Cited by 355
Borén, J., Olin, K., Lee, I., Chait, A., Wight, T. N., & Innerarity, T. L. (1998) · Journal of Clinical Investigation · doi:10.1172/jci2265 · Cited by 331
Role of the glucosamine pathway in fat-induced insulin resistance.
Hawkins, M. A., Barzilai, N., Liu, R., Hu, M., Chen, W., & Rossetti, L. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119390 · Cited by 323
Ji, Z. S., Brecht, W. J., Miranda, R. D., Hussain, M. M., Innerarity, T. L., & Mahley, R. W. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)82186-x · Cited by 305
Research works printed but not linked: 1
- Wight TN, The Vascular Extracellular Matrix (Lippincott Raven, Philadelphia, PA, 1996).
Cited by
Glycosaminoglycans and Glycosaminoglycan Mimetics in Cancer and Inflammation
Morla, S. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20081963 · Cited by 227
The heparanome and regulation of cell function: structures, functions and challenges
Ori, A. (2008) · Frontiers in bioscience · doi:10.2741/3007 · Cited by 185
A role for proteoglycans in vascular disease
Wight, T. N. (2018) · Matrix Biology · doi:10.1016/j.matbio.2018.02.019 · Cited by 171
Extracellular matrix dynamics in vascular remodeling
Ma, Z., Mao, C., Jia, Y., Fu, Y., & Kong, W. (2020) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00147.2020 · Cited by 129
Regulation of glycosaminoglycan structure and atherogenesis
Ballinger, M. L., Nigro, J., Frontanilla, K. V., Dart, A. M., & Little, P. J. (2004) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-004-3389-4 · Cited by 89
Metadata
- Authors
- Olsson, U., Östergren-Lundén, G., & Moses, J.
- Affiliations
- Sahlgrenska University Hospital (SE)
- Corresponding author
- Olsson, Urban
- Venue
- Glycoconjugate Journal
- Published
- 2001-10
- Volume
- 18
- Issue
- 10
- Pages
- 789-797
- ISSN
- 0282-0080 (ISSN-L)
- 1573-4986
- OpenAlex
- W1760442572
- Cited by
- 46
- References
- 41
- Citations by year
- 2026: 1 · 2025: 4 · 2024: 4 · 2023: 1 · 2021: 1 · 2020: 1 · 2019: 2 · 2018: 2 · 2016: 3 · 2015: 1 · 2012: 1
- FWCI
- 0.45
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- Locations
- Glycoconjugate Journal (publishedVersion)
- PubMed (publishedVersion)
- Funders
- AstraZeneca
- Vetenskapsrådet
- Magnus Bergvalls Stiftelse
- Socialstyrelsen
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Proteoglycans and glycosaminoglycans research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Keywords
- lipoprotein binding, heparan sulfate, dermatan sulfate, chondroitin sulfate, heparin, low-density lipoprotein, beta-VLDL, chylomicron remnants, apolipoprotein E, proteoglycans, atherosclerosis, lipoprotein metabolism, carbohydrate metabolism
- MeSH terms
- Autoradiography, Cardiovascular System, Glycosaminoglycans, Humans, Lipoproteins, Models, Biological, Protein Binding, Recombinant Proteins, Substrate Specificity, Sulfur Radioisotopes, Tumor Cells, Cultured, Electrophoretic Mobility Shift Assay
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.